Nova Eye Medical Limited (ASX:EYE)
Australia · Delayed Price · Currency is AUD 0.1400
+0.0050 (3.70%)
Sep 17, 2026, 3:53 PM AEST
Nova Eye Medical Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 0.96 | 5.06 | 6.15 | 7.42 | 8 |
Cash & Short-Term Investments | 0.96 | 5.06 | 6.15 | 7.42 | 8 |
Cash Growth | -80.93% | -17.82% | -17.09% | -7.26% | -55.06% |
Accounts Receivable | 5.01 | 4.09 | 3.9 | 1.93 | 2.05 |
Other Receivables | 0.1 | 0.09 | 0.18 | 1.18 | 1.72 |
Receivables | 5.11 | 4.18 | 4.08 | 3.11 | 3.77 |
Inventory | 3.24 | 2.81 | 4.28 | 3.81 | 3.54 |
Prepaid Expenses | 0.31 | 0.27 | 0.23 | 0.27 | 0.28 |
Total Current Assets | 9.62 | 12.33 | 14.75 | 14.6 | 15.59 |
Property, Plant & Equipment | 2.64 | 3.36 | 3.9 | 2.36 | 2.95 |
Other Intangible Assets | 6.02 | 6.86 | 7.03 | 8.45 | 7.17 |
Long-Term Deferred Charges | 3.18 | 3.89 | 4.13 | 4.87 | 10.85 |
Other Long-Term Assets | 0.13 | 0.07 | 0.07 | 0.07 | 0.07 |
Total Assets | 21.59 | 26.5 | 29.88 | 30.36 | 36.63 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 2.49 | 2.35 | 3.57 | 4.31 | 2.41 |
Accrued Expenses | 2.43 | 2.17 | 1.64 | 1.32 | 0.91 |
Current Portion of Leases | 0.61 | 0.63 | 0.48 | 0.64 | 0.54 |
Other Current Liabilities | - | - | - | 0.01 | 0.01 |
Total Current Liabilities | 5.53 | 5.15 | 5.68 | 6.27 | 3.86 |
Long-Term Leases | 1.78 | 2.38 | 2.87 | 0.89 | 1.4 |
Long-Term Deferred Tax Liabilities | - | - | - | - | 0.97 |
Total Liabilities | 7.31 | 7.54 | 8.55 | 7.17 | 6.23 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 59.1 | 58.94 | 52.71 | 45.18 | 37.44 |
Retained Earnings | -44.08 | -39.75 | -30.69 | -21.9 | -6.6 |
Comprehensive Income & Other | -0.75 | -0.23 | -0.69 | -0.09 | -0.44 |
Shareholders' Equity | 14.28 | 18.97 | 21.33 | 23.19 | 30.4 |
Total Liabilities & Equity | 21.59 | 26.5 | 29.88 | 30.36 | 36.63 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 2.39 | 3.02 | 3.35 | 1.53 | 1.94 |
Net Cash (Debt) | -1.43 | 2.04 | 2.8 | 5.89 | 6.06 |
Net Cash Growth | - | -27.27% | -52.41% | -2.79% | -57.05% |
Net Cash Per Share | -0.01 | 0.01 | 0.01 | 0.04 | 0.04 |
Filing Date Shares Outstanding | 284.88 | 284.71 | 229.06 | 190.33 | 145.58 |
Total Common Shares Outstanding | 284.87 | 284.15 | 228.82 | 190.33 | 145.58 |
Working Capital | 4.09 | 7.17 | 9.07 | 8.33 | 11.73 |
Book Value Per Share | 0.05 | 0.07 | 0.09 | 0.12 | 0.21 |
Tangible Book Value | 8.25 | 12.11 | 14.3 | 14.74 | 23.22 |
Tangible Book Value Per Share | 0.03 | 0.04 | 0.06 | 0.08 | 0.16 |
Machinery | 3.5 | 3.48 | 3.07 | 2.96 | 2.56 |